Clinical Trial Results: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating belapectin for prevention of esophageal varices in patients with NASH cirrhosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Esophageal Varices
• Nonalcoholic Steatohepatitis with Cirrhosis

Drugs mentioned

• Belapectin (belapectin)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2026-06-30